New research offers hope for vaccine and therapies for deadly infections

LA BioMed researcher leads team that finds antibodies to protect against mucormycosis

2013-12-20

(Press-News.org) Contact information: Laura Mecoy
lmecoy@labiomed.org
310-546-5860
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
New research offers hope for vaccine and therapies for deadly infections LA BioMed researcher leads team that finds antibodies to protect against mucormycosis LOS ANGELES – (Dec. 20, 2013) – Mucormycosis is a deadly infection that strikes people with weakened immune systems when certain types of fungi, called Mucorales, invade the patients' cells. A novel protein on the surface of the Mucorales cells, called CotH, makes this invasion possible.

In a finding that could lead to the development of a vaccine and therapies for mucormycosis, a research team at Los Angeles Biomedical Research Institute (LA BioMed) reported today in an online, ahead-of-print study in the Journal of Clinical Investigation that they can prevent human cell invasion and successfully treat mucormycosis in disease models using antibodies that block the CotH protein.

"There are no vaccines or effective therapies available today to halt the highly fatal mucormycosis infection, and there is an urgent need for these strategies to protect patients with weakened immune systems," said Ashraf S. Ibrahim, PhD, an LA BioMed lead researcher and corresponding author for the study. "Our research lays the groundwork for developing the antibodies to prevent and treat mucormycosis in high-risk patients. These findings also could lead to diagnostic tests for the disease."

Patients with weakened immune systems, malnutrition or acidosis (hyperglycemia or diabetic ketoacidosis) are at increased risk of infection. Dr Ibrahim's group found treatment with anti-CotH antibodies or CotH-targeted RNAi blocked the cell invasion and protected against mucormycosis. In a commentary accompanying the research, J. Andrew Alspaugh, MD, professor, Department of Medicine, Division of Infectious Diseases at Duke University Medical Center, discusses how these findings could contribute to the development of mucormycosis therapies.

### The study and the accompanying editorial will be published in the Jan. 2 edition of the Journal of Clinical Investigation. This work was supported by Public Health Service grants R01 AI063503 and R21 AI082414-01; the National Center for Advancing Translational Sciences through UCLA CTSI Grant UL1TR000124; grant R01 AI054928, and funding from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, No. HHSN272200900009C. Researchers contributing to the study were: Teclegiorgis Gebremariam, Mingfu Liu, Guanpingsheng Luo, Vincent Bruno, Quynh T. Phan, Alan J. Waring, John E. Edwards Jr., Scott G. Filler and Michael R. Yeaman.

About LA BioMed

Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved diagnostics and treatments for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit http://www.LABioMed.org

ELSE PRESS RELEASES FROM THIS DATE:

UBC-VCH scientists use drug to repair rare birth defect

2013-12-20

UBC-VCH scientists use drug to repair rare birth defect Success in mouse model is first instance of drug reversing a congenital deformity University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, ...

Enlisting cells' protein recycling machinery to regulate plant products

2013-12-20

Enlisting cells' protein recycling machinery to regulate plant products New molecular tools for controlling production of compounds important for flavors, human health, and biofuels UPTON, NY--Scientists at the U.S. Department of Energy's Brookhaven ...

New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells

2013-12-20

New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells The study presents the first description of a set of related nuceleotide sequences essential for the role of these small molecules in ...

Efforts to curb climate change require greater emphasis on livestock

2013-12-20

Efforts to curb climate change require greater emphasis on livestock CORVALLIS, Ore. – While climate change negotiators struggle to agree on ways to reduce carbon dioxide (CO2) emissions, they have paid inadequate attention to other greenhouse gases associated ...

Birth of black hole kills the radio star

2013-12-20

Birth of black hole kills the radio star Research clears telescope, disproves long-held theory Astronomers led by a Curtin University researcher have discovered a new population of exploding stars that "switch off" their radio transmissions before collapsing ...

An earthquake or a snow avalanche has its own shape

2013-12-20

An earthquake or a snow avalanche has its own shape However, it is crucial what one observes – paper fracture or the avalanching of snow. The results were just published in the Nature Communications journal. Avalanches of snow or earthquakes can be described in other ...

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

New research offers hope for vaccine and therapies for deadly infections

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: